Patents by Inventor Sameer AGNIHOTRI

Sameer AGNIHOTRI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ERK5 INHIBITORS FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS
    Publication number: 20220031710
    Abstract: The present disclosure relates to uses of an ERK5 inhibitor, e.g., ERK5-in-1, for treating a glioma in a pediatric human subject. In certain embodiments, the glioma can be a pediatric high-grade glioma (PHGG), e.g., a diffuse intrinsic pontine glioma (DIPG), and/or a H3.3-mutated glioma (e.g., a H3K27M-mutated glioma). The present disclosure further provides pharmaceutical compositions and kits that include an ERK5 inhibitor.
    Type: Application
    Filed: October 21, 2021
    Publication date: February 3, 2022
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Sameer Agnihotri, Alberto Broniscer, Ian F. Pollack
  • Use of TG02 for treating gliomas in pediatric subjects
    Patent number: 11173160
    Abstract: The present disclosure relates to uses of TG02, for treating a glioma in a pediatric human subject. In certain embodiments, the glioma can be a pediatric high-grade glioma (PHGG), e.g., a diffuse intrinsic pontine glioma (DIPG), and/or a H3.3-mutated glioma (e.g., a H3K27M-mutated glioma). The present disclosure further provides pharmaceutical compositions and kits that include an ERK5 inhibitor.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: November 16, 2021
    Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, ADASTRA PHARMACEUTICALS, INC.
    Inventors: Sameer Agnihotri, Alberto Broniscer, Ian F. Pollack, Thomas M. Estok
  • USE OF TG02 FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS
    Publication number: 20200368242
    Abstract: The present disclosure relates to uses of TG02, for treating a glioma in a pediatric human subject. In certain embodiments, the glioma can be a pediatric high-grade glioma (PHGG), e.g., a diffuse intrinsic pontine glioma (DIPG), and/or a H3.3-mutated glioma (e.g., a H3K27M-mutated glioma). The present disclosure further provides pharmaceutical compositions and kits that include an ERK5 inhibitor.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Applicants: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, ADASTRA PHARMACEUTICALS, INC.
    Inventors: Sameer AGNIHOTRI, Alberto BRONISCER, Ian F. POLLACK, Thomas M. ESTOK